Chris Harper

Biography

 "Before I meet a new patient, I’m already thinking about how I can use my knowledge to provide the best possible treatment available to give the person in front of me the best possible outcome. Without access to the latest equipment, and the confidence to know that I’m backed by a highly skilled team, this wouldn’t be possible." Chris completed his initial medical and radiation oncology training in Western Australia, before undertaking post-graduate studies at Middlesex Hospital (UK), Princess Margaret Hospital (Toronto, Canada), and the Shands Cancer Centre (University of Florida, Gainesville, USA). He is currently the medical director at Perth Radiation Oncology in Wembley and head of the Department of Radiation Oncology at Fiona Stanley Hospital. He also holds a clinical staff position at Sir Charles Gairdner Hospital and is accredited as a visiting consulting at a number of private hospitals. Chris has specialised expertise in advanced radiotherapy techniques including stereotactic radiosurgery, stereotactic body radiation therapy, episcleral plaque brachytherapy for choroidal melanoma, and image guided radiation therapy, including IMRT. He has also completed training on the use of the CyberKnife® Robotic Radiosurgery System. As an expert in his field, Chris has been involved with many notable committees. He was chairman of the Radiation Oncology Economics Committee, on the board of the Faculty of Radiation Oncology of the Royal Australian and New Zealand College of Radiologists (RANZCR), and more recently chairman of the Australian Association of Private Radiation Oncology Practices (AAPROP), to name but a few. He has also been a guest editor for the International Journal of Stereotactic Radiosurgery. Chris is a member of the American Society for Therapeutic Radiation and Oncology (ASTRO), the International Stereotactic Radiosurgery Society (ISRS) and the Trans Tasman Radiation Oncology Group (TROG). He has published over ten papers and is involved in ongoing research projects relating to predominantly prostate, intracranial, lung and spinal tumours. Chris’ key clinical interests are in neuro-oncology (brain, skull base and ocular tumours), skin, upper and lower gastrointestinal tumours, head and neck cancers, and urological cancers. His current major technical interests are in the field of stereotactic ablative radiation therapy (SABR).

Research Interest

 Cancer